Bio pharmaceutical company: Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) was founded in 1876. Headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE: LLY) has 35000 full-time employees. It is a global R&D based pharmaceutical company with a market value of nearly 100 billion dollars, and also the first enterprise to list insulin and produce antibiotics in the world.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

Eli Lilly and Company (LLY)

Eli Lilly is a global R&D based pharmaceutical company The largest in the world We are one of the enterprises that are committed to providing innovative medical care programs based on drugs for all mankind, so that people can live longer, healthier and more dynamic lives. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

Eli Lilly is one of the world's top ten famous pharmaceutical companies engaged in drug research, production and sales. It is the world's first listed insulin and antibiotic manufacturer, and has formed a therapeutic field focusing on the central nervous system, anti-tumor, endocrine system, anti infection, osteoporosis and animal medicine. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

At present, Eli Lilly's drugs are sold in 143 countries, with large research and development facilities in 13 countries and clinical trials in more than 60 countries. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

Eli Lilly's main products are clenbuterol, Ractopamine, Prozac, Zeprexa, Humalog, Humulin, Cialis, and Pfizer And the hyperactivity drug Strattera. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

In 2008, Eli Lilly monsanto Bought POSILAC product, which is a hormone artificial hormone (rBST) applied to cows. It claims that it can increase the milk production of cows, but it will increase the probability of cows suffering from mastitis. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

List of Lilly products

• 1983 Youbi Forest ® (Humulin) for type 1 and type 2 diabetes
• 1987 Humatrope ® Used to treat growth disorders caused by growth hormone deficiency in children
• 1995 Gemcitabine ® (Gemzar) for first-line treatment of non-small cell lung cancer
• 1995 ReoPro ® Prevention of cardiac ischemic complications in patients undergoing coronary intervention (e.g. revascularization)
• 1996 Zapla ® (Zyprexa) for treatment of schizophrenia
• 1996 Yomil ® Humalog for type 1 and type 2 diabetes
• 1998 Yiwei Te ® (Evista) for prevention of postmenopausal osteoporosis in women
• 2001 Xigris ® Treatment of adult severe sepsis with high risk of death
• 2002 Forteo ® Treatment of male osteoporosis and postmenopausal female osteoporosis with high fracture risk
• 2003 Xieli ® (Cialis) in the treatment of male erectile dysfunction
• 2003 Zestar ® (Strattera) for children, adolescents and adults with attention deficit and hyperactivity disorder
• 2004 Libitai ® (Alimta) for malignant pleural mesothelioma)
• 2004 Xinbaida ® (Cymbalta) in the treatment of depressive disorder
• 2004 Erbitux ® For epidermal growth factor receptor blocking in the treatment of metastatic colorectal cancer (EGFR expressing)
• 2004 Symbyax ® Treatment of depressive episode of bipolar affective disorder Yentreve ® Treatment of stress urinary incontinence (approved outside the United States)
• 2005 Baimida ™ (Byetta) in the treatment of type 2 diabetes mellitus with failure of oral hypoglycemic drugs (combined with biguanide, sulfonylurea or biguanide plus sulfonylurea)
• 2009 Adcirca ™ (Tadanafil) for the treatment of pulmonary hypertension (USA)
• 2009 Efient ® Prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. (USA and Europe) (vs. Japan Daiichi Sankyo Co Joint R&D)
• In 2019, acquired Loxo Oncology, Inc. and obtained its cancer treatment drug Vitrakvi (larotrectinib)

History Encyclopedia of Eli Lilly

In the 1920s, in cooperation with Banting and Best of the University of Toronto, insulin was extracted and purified for the treatment of diabetes. Diabetes was a fatal disease at that time, and there was no effective treatment The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

In 1923, Lilly launched the first animal insulin insulin insulin in the world and carried out large-scale production The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

In 1943, penicillin, the first antibiotic in human history, was first produced on a large scale The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

In 1958, the powerful antibiotic vancomycin was born, which is still the last line of defense for patients with severe hospital infection. Erythromycin was introduced, bringing more options for patients with penicillin allergy The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lly.html

In 1960, Eli Lilly and Company introduced a new class of oral and injection antibiotics cephalosporins. In the following 20 years, a major breakthrough was made and such antibiotics were produced in large scale, including Keflex and Kefzol

In 1963, Eli Lilly and Company developed vinblastine anticancer drugs

In the 1970s, Eli Lilly and Company launched the innovative drug Dobutrex to treat cardiovascular diseases

In 1979, Lilly Pharmaceuticals launched Xikelao, becoming the world's best-selling oral antibiotic

In 1982, the world's first artificial gene synthetic human insulin eucrine was the world's first human medical product created using recombinant DNA technology, and also the most significant breakthrough in the field of diabetes since the 1920s

In 1986, the treatment drug for depression Baiyoujie was honored as the "medicine of the century"

In the 1990s, Eli Lilly launched ReoPro to prevent thrombosis after some heart operations

In 1995, gemcitabine for pancreatic cancer and non-small cell lung cancer is still the "gold standard". It has since been approved for the treatment of breast cancer and recurrent ovarian cancer

In 1996, it is still the world's best-selling schizophrenic drug Zaipule

In 1996, the world's first human insulin analogue, Umil

In 1999, Lilly and Takeda Cooperate to launch Actos, an oral hypoglycemic drug

In 1998, Yvette for prevention and treatment of postmenopausal osteoporosis

In 2001, Eli Lilly and Company launched another pioneering drug of the same kind, Xigris, to treat adult severe sepsis with high risk of death

In 2002, Eli Lilly created a new generation of drug Forteo to treat osteoporosis and promote new bone regeneration

In 2003, Xieli, a new drug for male erectile dysfunction

In 2004, Libital, which was used to treat malignant pleural mesothelioma and non-small cell lung cancer, was praised as "a new breakthrough in refractory tumors"

In 2003, Zesta, the first non stimulant drug for attention deficit and hyperactivity disorder

In 2004, Eli Lilly and Company took a two pronged approach to treat depression, mental and physical symptoms at the same time Cymbalta

In 2004, Lilly launched the first and only drug Symbyax to treat two-way depression

In 2005, since the 1990s, a breakthrough new drug named BEMIDA, which has been used to treat type 2 diabetes, created a new type of diabetes treatment drug - incretin analogue

In 2009, Eli Lilly and Company launched Affint ® ， Prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. (Jointly developed with Japan First Pharmaceutical Sankyo Co., Ltd.)

On May 8, 2018, Eli Lilly announced its acquisition of about 1.6 billion dollars Armo BioSciences 。

On May 14, 2018, Eli Lilly purchased AurKa Pharma for about 575 million dollars.

On September 20, 2018, Lilly Pharmaceutical split its animal health business Elanco Animal Health Inc. (U.S. stocks: ELAN) New York stock exchange It was listed at a price of 24 US dollars per share, issued 62.9 million shares and raised 1.5096 billion US dollars.

In January 2019, Eli Lilly and Company announced that they agreed to acquire the company with US $8 billion Loxo Oncology, Inc. 。

In March 2019, the original Lilly Lilly Mobile Insurance The division completed the split and became an independent listed company with Lilly. Lilly focused on its drug research and development in the fields of cancer, diabetes, autoimmune diseases, pain and other diseases.

In January 2020, Lilly acquired at a price of US $18.75 per share Dermira To strengthen its R&D strength in the field of autoimmune diseases.

In October 2020, Lilly acquired Disarm Therapeutics to strengthen its product research and development in peripheral neuropathy and other neurological diseases.

November 2020, USA food The Food and Drug Administration has issued an emergency use authorization (EUA) for research monoclonal antibody therapy bamlanivimab, which is used to treat mild to moderate adult and child patients Covid-19 。

In December 2020, Lilly announced that it would acquire the company with US $1 billion Prevail Therapeutics Inc To expand its product line in the field of gene therapy for neurodegenerative diseases.

On January 22, 2021, Eli Lilly and Company, LLC announced the successful completion of Prevail Therapeutics Inc. Acquisition of.

On May 18, 2021, FDA accepted the Tyvyt (sinilimab) application of Eli Lilly and used it in combination with Eli Lilly's Alimta (pemetrexed) and platinum chemotherapy for newly diagnosed non-small cell lung cancer.

In July 2021, the company announced that it would acquire Protomer Technologies at a price of more than $1 billion.

In 2022, Lilly's distribution of COVID-19 antibody drugs was suspended due to the lack of efficacy for emerging omicron variants.

In February 2022, the second COVID-19 monoclonal antibody therapy (bebtelovimab) developed in cooperation with AbCelera was authorized for emergency use, and the US government promised to spend 720 million dollars to buy up to 600000 doses.

In October 2022, Lilly agreed to acquire at a price of up to 610 million dollars Akouos The transaction aims to expand Lilly's business in the field of gene therapy, focusing on the treatment of inner ear diseases.

On June 20, 2023, Lilly and DICE Therapeutics, Inc. (DICE) announced that Lilly had reached the final agreement to acquire DICE. The transaction was completed in August of the same year.

On June 29, 2023, Eli Lilly agreed to acquire at a cash price of $14.92 per share (with a total value of about $35 million) Sigilon Therapeutics (NASDAQ:SGTX)。

On July 14, 2023, Lilly and Versanis Bio announced that they had reached a final agreement. Lilly would acquire Versanis, a private clinical stage focused on developing new drugs for heart metabolic diseases Biopharmaceutical Company 。

On August 14, 2023, Lilly announced the completion of the acquisition of Versanis Bio and Sigilon Therapeutics, and continued to expand its diabetes and weight loss drug product lines.

On October 3, 2023, Eli Lilly (NYSE: LLY) agreed to acquire a cancer drug developer at a cash price of US $12.50 per share (transaction value of about $1.4B) POINT Biopharma Global (NASDAQ:PNT)。 The transaction was completed on December 27, 2023.

On October 18, 2023, Eli Lilly, an American pharmaceutical giant, announced the acquisition of Mablink Bioscience, a company focusing on the development of cancer antibody drug conjugates Biotechnology Company 。

On November 21, 2023, Eli Lilly participated in the Alto Neuroscience, Inc. $45 million in Series C financing.

Eli Lilly and Company (LLY) US equity investment